Group 1 - The core announcement is that Jingyou Pharmaceutical (00858.HK) has entered into a share repurchase agreement with Changchun Han Du Ding Ye Real Estate Planning and Sales Co., Ltd. for approximately 10.06% of the shares in its indirect non-wholly owned subsidiary, Changchun Jingyou, for a price of RMB 4.4 million (approximately HKD 4.84 million) [1] - Following the completion of the share repurchase, the repurchased shares will be canceled, resulting in an increase in the shareholding percentage of existing shareholders in Changchun Jingyou. Consequently, the group's stake in Changchun Jingyou will rise to 89.46% [1] - After the share repurchase and cancellation, Changchun Jingyou will continue to be an indirect non-wholly owned subsidiary of the group [1]
精优药业(00858.HK)回购长春精优10.06%股份 代价440万元